Dr. Lifshitz is a proficient Microbiologist who is experienced in scientific management of early stage research and development programs in the area of anti-microbial therapeutics. Prior to joining Trobix Bio, Ziv served as a Senior Scientist at Zolex Ltd., a company which develops novel treatment against antibiotic-resistant Staphylococcus Aureus infections. Here, he led the development steps from hit screening and characterization to demonstrate efficacy in pre-clinical studies. Previously, Ziv served as Research Investigator in the Division of Infectious Diseases at Tel Aviv Sourasky Medical Center. There, he led the clinical research of antibiotic-resistant bacteria, mechanisms of infection and routes of dissemination. Ziv attained novel scientific understanding by using the implementation of NGS Technology and became an expert in investigating the in-vivo pathogenesis of various infectious agents using different animal models.
Ziv holds a PhD from Tel Aviv University where he investigated the molecular pathogenesis mechanisms of the human pathogen Legionella Pneumophila.